Spark Therapeutics Inc. has announced a slight delay to completing the US submission of what is expected to the first BLA involving a gene therapy for a genetic disease, from the end of 2016 to early in 2017.
The company has also released clinical data on a further nine patients treated with its potential gene therapy, voretigene neparvovec...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?